Evidence map›Paper›PMID 38089733›Full record

ArticleCase reports in oncology

Contemplation of the Effect of Nivolumab Plus Cabosantinib Therapy on Cerebral Hemorrhage in Patients with Brain Metastasis of Renal Cell Carcinoma: A Case Report.

Yasufumi Sato, Yoshihide Kawasaki, Yohei Satake, Yoshiteru Shimoda, Hiromichi Katayama, Takuma Sato, Shuichi Shimada, Naoki Kawamorita, Shinichi Yamashita, Masayuki Kanamori and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yasufumi SatoDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yoshihide KawasakiDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yohei SatakeDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yoshiteru ShimodaDepartment of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hiromichi KatayamaDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takuma SatoDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Shuichi ShimadaDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Naoki KawamoritaDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Shinichi YamashitaDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Masayuki KanamoriDepartment of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Akihiro ItoDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the response to combination therapy has been reported in patients with brain metastases from advanced renal cancer, treatment-related cerebral hemorrhage has not been adequately studied. The CheckMate 9ER clinical trial of nivolumab and cabozantinib excluded patients with brain metastases. Therefore, the associated treatment outcomes in these patients with brain metastases are unclear. Herein, we report a case of bleeding from brain metastases in a patient with advanced renal cancer after gamma knife combination therapy with nivolumab and cabozantinib. Fortunately, the cerebral hemorrhage of the patient was alleviated by conservative treatment. Despite treatment interruption, the metastatic lesions reduced in size, and treatment was gradually resumed. In this case study, we report the risk of cerebral hemorrhage in combination therapy for brain metastasis cases, how to manage hemorrhage cases, and their prognosis.

Indexed as

CabozantinibCase reportCerebral hemorrhageNivolumabRenal cell carcinoma

Identifiers

PMID38089733
PMCPMC10715752
OpenAlexW4389606627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.